Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025;9(3):253-256.

Effect of stereotactic body radiotherapy beyond primary target in prostate cancer

Jay P Sahu  1 , Trinanjan Basu  1 , Shounak J Kamat  1 , Ajinkya Gadekar  1 , Rohith R Menon  1 , Ghazala K Roshan  1
Affiliations
  • PMID: 40476280
  • PMCID: PMC12136679 (available on )

Effect of stereotactic body radiotherapy beyond primary target in prostate cancer

Jay P Sahu et al. J Radiosurg SBRT. 2025.
No abstract available

Keywords: PSA; PSMA PET CT; SBRT; abscopal effect; prostate cancer.

PubMed Disclaimer

References

    1. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated Int J Radiat Oncol Biol Phys 2004. 58 (3): 862–870 10.1016/j.ijrobp.2003.09.012 - DOI - PubMed
    1. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis Oncogene 2003. 22 (37): 5897–5906 - PubMed
    1. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer JAMA Netw Open 2019. 2 (2): e188006 10.1001/jamanetworkopen.2018.8006 - DOI - PMC - PubMed
    1. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial Lancet 2019. 394 (10196): 385–395 10.1016/S0140-6736(19)31131-6 - DOI - PubMed
    1. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N, PACE Trial Investigators Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Lancet Oncol 2019. 20 (11): 1531–1543 10.1016/S1470-2045(19)30569-8 - DOI - PMC - PubMed

LinkOut - more resources